Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Under the joint agreement, Merck KGaA receives 50% of profit/loss from Japan sales, while ImClone and BMS each receive 25%; ImClone additionally receives a…
Under the original 2007 co-development and co-commercialization agreement, Merck Serono Co. Ltd. distributed Erbitux and recorded sales for the collaboration,…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Amended Erbitux Japan co-development; Merck KGaA 50% / ImClone & BMS 25% each profit; 4.75% royalty to ImClone. Source: BioSpace, Fierce Biotech.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / ImClone Systems Incorporated (this deal) | 2007 | — | — |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Threshold Pharmaceuticals, Inc. | 2012 | $550M | — |
← Browse all deals · How we score deals
More: 2007 deals · Merck KGaA deals